Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 09, 2024 09:30 ET | Source: SOHM, Inc.

SOHM Files Provisional Patent on ABBIE’s ‘Smart Gene-Editing’ That Uses Latest Enzymes and Guide RNA to Resolve Off-Target Gene-Editing Limitations

CHINO HILLS, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- via IBN -- SOHM, Inc. (OTC PINK: SHMN) (the “Company”), a pharmaceutical, nutraceutical, cosmeceutical and biotech Company that manufactures...
January 09, 2024 08:00 ET | Source: electroCore, Inc.

electroCore Expands Intellectual Property Portfolio

ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
January 08, 2024 09:00 ET | Source: Route 92 Medical, Inc.

Route 92 Medical Announces the 100th Patent for its Neurovascular Intervention Portfolio

Route 92 Medical announces the receipt of its 100th patent for its rapidly growing portfolio of neuromuscular intervention products.
January 08, 2024 08:55 ET | Source: PharmAla Biotech

PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance

PharmAla announces that its novel P1 molecule has been accepted by USPTO to its accelerated "Patent Prosecution Highway"
January 08, 2024 08:22 ET | Source: Liquidia Corporation

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal CircuitRequests declaration that ‘327 patent is not infringed, is...
January 08, 2024 07:30 ET | Source: Anavex Life Sciences Corp.

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
January 08, 2024 07:00 ET | Source: ADMA Biologics, Inc.

ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update

4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320...
January 07, 2024 15:00 ET | Source: Dewpoint Therapeutics

Dewpoint Therapeutics Filed Multiple Patent Applications with the US Patent Office on Novel Composition of Matter for the Treatment of ALS

Patent applications reinforce Dewpoint’s leadership in the discovery of condensate-modifying drugs (c-mods) to treat diseases of high unmet needNew first-in-class composition of matter targeting...
January 04, 2024 15:05 ET | Source: Faraday Pharmaceuticals

Faraday Pharmaceuticals Announces Agreement with FDA on Interim Analysis of Phase 3 IOCYTE AMI-3 Trial Data and EU Notice of Intention to Grant Patent

Interim analysis estimated to occur in late Q2 2024 and will be based on at least 50% of anticipated primary outcomesPivotal Phase 3 trial continues to progress with over 75% of initially-planned...
January 04, 2024 08:00 ET | Source: Indaptus Therapeutics

European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform...